Phase 3 from a position of strength: Fresh funding allows Pentixapharm to enter Phase 3 from a position ...

Pentixapharm sits at the intersection of a high-prevalence indication and one of the fastest-growing fields of medicine: radiopharma. Following the recent capital increase, the company is now well ...